[go: up one dir, main page]

MA33229B1 - Immunoconjugues anti-mesotheline et leurs utilisations - Google Patents

Immunoconjugues anti-mesotheline et leurs utilisations

Info

Publication number
MA33229B1
MA33229B1 MA34308A MA34308A MA33229B1 MA 33229 B1 MA33229 B1 MA 33229B1 MA 34308 A MA34308 A MA 34308A MA 34308 A MA34308 A MA 34308A MA 33229 B1 MA33229 B1 MA 33229B1
Authority
MA
Morocco
Prior art keywords
antibodies
immunoconjugates
mesothelin
tumors
agents
Prior art date
Application number
MA34308A
Other languages
English (en)
Inventor
Antje Kahnert
Kerstin Berhoerster
Iring Heisler
Charlotte Christine Kopitz
Joachim Schumacher
Original Assignee
Bayer Pharma AG
Cabinet Ghars
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Cabinet Ghars filed Critical Bayer Pharma AG
Publication of MA33229B1 publication Critical patent/MA33229B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur des immunoconjugués composés d'anticorps, par exemple d'anticorps monoclonaux ou de fragments d'anticorps qui se lient à la mésothéline, qui sont conjugués à des agents cytotoxiques, par exemple, la maytansine ou des dérivés de celle-ci, et/ou co-administrés ou formulés avec un ou plusieurs agents anti-cancéreux supplémentaires. Les immunoconjugués de l'invention peuvent être utilisés dans les procédés de l'invention pour traiter et/ou diagnostiquer et/ou surveiller des cancers, par exemple des tumeurs solides. Les immunoconjugués comprennent des anticorps et des fragments fonctionnels contenant de telles régions de liaison à l'antigène qui sont spécifiques pour le polypeptide de mésothéline de 40 kDa ancré à la membrane qui est surexprimé dans plusieurs tumeurs, telles que des tumeurs pancréatiques et ovariennes, des mésothéliomes et des cellules du cancer du poumon.
MA34308A 2009-04-29 2010-04-16 Immunoconjugues anti-mesotheline et leurs utilisations MA33229B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09005909 2009-04-29
PCT/EP2010/002342 WO2010124797A1 (fr) 2009-04-29 2010-04-16 Immunoconjugués anti-mésothéline et leurs utilisations

Publications (1)

Publication Number Publication Date
MA33229B1 true MA33229B1 (fr) 2012-04-02

Family

ID=42332769

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34308A MA33229B1 (fr) 2009-04-29 2010-04-16 Immunoconjugues anti-mesotheline et leurs utilisations

Country Status (41)

Country Link
US (5) US9084829B2 (fr)
EP (2) EP3292874B1 (fr)
JP (3) JP5616433B2 (fr)
KR (1) KR101681795B1 (fr)
CN (2) CN106177984B (fr)
AR (1) AR076284A1 (fr)
AU (1) AU2010243942B2 (fr)
BR (1) BRPI1014637B1 (fr)
CA (1) CA2760114C (fr)
CL (1) CL2011002681A1 (fr)
CO (1) CO6450601A2 (fr)
CR (1) CR20110566A (fr)
CU (1) CU23929B1 (fr)
CY (2) CY1119738T1 (fr)
DK (2) DK3292874T3 (fr)
DO (1) DOP2011000331A (fr)
EC (1) ECSP11011423A (fr)
ES (2) ES2790732T3 (fr)
GT (1) GT201100269A (fr)
HN (1) HN2011002834A (fr)
HR (2) HRP20180015T1 (fr)
HU (2) HUE049795T2 (fr)
IL (1) IL215769A (fr)
JO (1) JO3486B1 (fr)
LT (2) LT3292874T (fr)
MA (1) MA33229B1 (fr)
MX (1) MX2011011365A (fr)
MY (1) MY158624A (fr)
NO (1) NO2424569T3 (fr)
NZ (1) NZ596013A (fr)
PE (1) PE20120556A1 (fr)
PL (2) PL2424569T3 (fr)
PT (2) PT3292874T (fr)
SG (1) SG175254A1 (fr)
SI (2) SI2424569T1 (fr)
TN (1) TN2011000547A1 (fr)
TW (2) TW201529084A (fr)
UA (2) UA106492C2 (fr)
UY (1) UY32560A (fr)
WO (1) WO2010124797A1 (fr)
ZA (1) ZA201107757B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32560A (es) * 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
WO2012087962A2 (fr) 2010-12-20 2012-06-28 Genentech, Inc. Anticorps et immunoconjugués anti-mésothéline
CN107537040A (zh) 2011-03-29 2018-01-05 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
SG193996A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
AU2013306076B2 (en) * 2012-08-21 2018-01-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
WO2014043523A1 (fr) * 2012-09-14 2014-03-20 The Johns Hopkins University Compositions et procédés pour rendre des cellules tumorales sensibles à la destruction à médiation par des lymphocytes t cd8+
EP2900695B1 (fr) * 2012-09-27 2018-01-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps dirigés contre la mésothéline et procédés d'induction d'une activité anticancéreuse puissante
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
EP3060256B1 (fr) * 2013-10-25 2019-05-08 Bayer Pharma Aktiengesellschaft Nouvelle formulation stable
TWI541022B (zh) * 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
WO2015200773A1 (fr) * 2014-06-27 2015-12-30 Oregon Health & Science University Composés se liant au dystroglycane et utilisations de ceux-ci
EP4218724A3 (fr) * 2014-08-29 2023-08-16 Corium Pharma Solutions, Inc. Réseaux à microstructures pour l'administration d'agents actifs
AU2015349985A1 (en) 2014-11-19 2017-05-25 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
NZ740855A (en) * 2015-08-21 2022-04-29 Crage Medical Co Ltd Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
MA43959A (fr) 2016-02-03 2018-12-12 Amgen Res Munich Gmbh Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
CA3013125A1 (fr) 2016-02-05 2017-08-10 Immunogen, Inc. Procede efficace de preparation de conjugues agent de liaison cellulaire-agent cytotoxique
CA3027302A1 (fr) 2016-06-20 2017-12-28 F-Star Beta Limited Elements de liaison (1)
WO2018048975A1 (fr) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Utilisation d'un anticorps anti-pd-1 en combinaison avec un anticorps anti-mésothéline dans le traitement du cancer
KR101966362B1 (ko) 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
WO2019105835A1 (fr) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinaisons de copanlisib et d'anetumab ravtansine
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
JP2021529516A (ja) * 2018-06-18 2021-11-04 アンウィタ バイオサイエンシス， インク． サイトカイン融合タンパク質及びその使用
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
IL280002B2 (en) 2018-07-12 2025-05-01 F Star Beta Ltd Antibody molecules that bind CD137 and OX40
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
WO2020011964A1 (fr) 2018-07-12 2020-01-16 F-Star Beta Limited Molécules d'anticorps qui se lient à pd-l1 et cd137
JP7458981B2 (ja) 2018-08-06 2024-04-01 第一三共株式会社 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
WO2020234114A1 (fr) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Nouvelle formulation stable à haute concentration pour anetumab ravtansine
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
AU2021353004A1 (en) 2020-09-30 2023-04-13 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
CN116745323A (zh) 2021-01-22 2023-09-12 拜耳股份有限公司 Lrrc15抗体及其缀合物
US20250154201A1 (en) * 2022-02-10 2025-05-15 Kyungpook National University Industry-Academic Cooperation Foundation Peptide binding to mesothelin, and use thereof
KR20230121560A (ko) 2022-02-10 2023-08-18 경북대학교 산학협력단 메소세린에 결합하는 펩타이드 및 이의 용도
WO2024027708A1 (fr) 2022-08-02 2024-02-08 诺纳生物（苏州）有限公司 Conjugué anticorps-médicament msln
WO2025113643A1 (fr) 2023-12-01 2025-06-05 Gilead Sciences Inc. Protéine de fusion anti-fap-light et utilisation associée
WO2025259871A1 (fr) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anticorps anti-ccr8 et leurs utilisations

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1437180A (en) 1920-12-16 1922-11-28 Wahl Co Mechanical pencil
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (fr) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
CA2093022C (fr) 1990-10-05 2005-02-22 Michael W. Fanger Immunostimulation ciblee au moyen de reactifs bispecifiques
EP0557300B1 (fr) 1990-10-29 1997-11-19 Chiron Corporation Anticorps bispecifiques, methodes de production et utilisation desdits anticorps
US5773280A (en) 1992-03-20 1998-06-30 The Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
WO1992019973A1 (fr) 1991-04-26 1992-11-12 Surface Active Limited Nouveaux anticorps et procedes d'utilisation de ces anticorps
US5407653A (en) 1991-06-26 1995-04-18 Brigham And Women's Hospital Evaluation of the multidrug resistance phenotype
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
ES2193143T3 (es) 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
JPH0699141A (ja) * 1992-09-21 1994-04-12 Kubota Corp 石抜装置
JPH06124641A (ja) * 1992-10-08 1994-05-06 Mitsubishi Electric Corp 回路遮断器
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
CA2115811A1 (fr) 1993-02-17 1994-08-18 Claus Krebber Methode de selection in vivo de proteines fixatrices de ligands
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
JP3659261B2 (ja) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
JPH0945957A (ja) * 1995-07-28 1997-02-14 Oki Electric Ind Co Ltd 端面発光型ｌｅｄアレイの製造方法及びその検査方法
JP3724015B2 (ja) * 1995-08-08 2005-12-07 コベルコ建機株式会社 パイロット切換弁の応答性可変装置
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US7375183B1 (en) * 1996-01-05 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof
ATE254931T1 (de) 1996-01-05 2003-12-15 Us Gov Health & Human Serv Mesothelinantigen, verfahren und testsatz zur targetierung
JP2002501721A (ja) 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
CA2309321A1 (fr) 1997-11-10 1999-05-20 G.D. Searle & Co. Emploi d'iminosucres alkyles pour traiter la resistance multiple aux anticancereux
WO1999028471A2 (fr) * 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services ANTICORPS, NOTAMMENT DES MOLECULES Fv, IMMUNOCONJUGUES PRESENTANT UNE GRANDE AFFINITE DE LIAISON POUR LA MESOTHELINE ET PROCEDES D'UTILISATION CORRESPONDANTS
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
WO2000050900A2 (fr) 1999-02-26 2000-08-31 Pacific Northwest Research Institute Techniques et compositions pour le diagnostic de carcinomes
DK1133565T3 (da) 1999-07-02 2011-01-24 Morphosys Ag Generering af specifikke bindingspartnere til (poly)peptider, som der kodes for af genomiske DNA-fragmenter eller EST'er
DE60041119D1 (de) 1999-07-20 2009-01-29 Morphosys Ag Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
EP1229934B1 (fr) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
WO2001039744A2 (fr) 1999-11-30 2001-06-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Liposomes radiosensibles
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
NZ537610A (en) 2002-07-02 2006-07-28 Smithkline Beecham Corp Stable formulations of the C242 antibody
EP2281577B1 (fr) 2003-05-14 2016-11-16 ImmunoGen, Inc. Composition constituee de conjuges de medicaments
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
AU2003282780A1 (en) 2003-08-08 2005-03-07 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
CN109045307A (zh) * 2004-06-01 2018-12-21 健泰科生物技术公司 抗体-药物偶联物和方法
EP2468304A3 (fr) * 2005-02-11 2012-09-26 ImmunoGen, Inc. Procédé de préparation de conjugués de médicaments stables
EP2322560B1 (fr) * 2005-03-10 2013-09-04 Morphotek, Inc. Anticorps anti-mésothéline
US20090047211A1 (en) * 2005-05-12 2009-02-19 The Govt. Of The U.S. As Represented By The Sec. Of The Dept. Of Health And Human Services Anti-mesothelin antibodies useful for immunological assays
PL3620171T3 (pl) 2005-05-18 2022-08-08 Morphosys Ag Przeciwciała anty-gm-csf i ich zastosowania
CN101282993A (zh) 2005-06-02 2008-10-08 阿斯利康公司 针对cd20的抗体和其用途
RU2447889C2 (ru) * 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
JP2009503105A (ja) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
DK1948180T3 (da) * 2005-11-11 2013-05-27 Boehringer Ingelheim Int Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
US20070237758A1 (en) 2005-11-22 2007-10-11 Anthony Barry Immunoglobulin fusion protein formulations
EP1854478A1 (fr) 2006-05-12 2007-11-14 Cytos Biotechnology AG Composition vaccinale comprenant des conjugués nicotine-porteur
US8128926B2 (en) * 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
PL2195017T3 (pl) * 2007-10-01 2015-03-31 Bristol Myers Squibb Co Ludzkie antyciała, które wiążą mezotelinę i ich zastosowania
US9023351B2 (en) * 2007-11-26 2015-05-05 Bayer Intellectual Property Gmbh Anti-mesothelin antibodies and uses thereof
CN104524590B (zh) * 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
US20090298088A1 (en) * 2008-05-30 2009-12-03 Belyaev Alexander S Cleavable catalytic binding and detection system
AU2009271401A1 (en) * 2008-06-16 2010-01-21 Immunogen Inc. Novel synergistic effects
ES2643411T3 (es) * 2008-08-05 2017-11-22 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a la proteína del complemento C5
CN102413839A (zh) 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
WO2010111282A1 (fr) * 2009-03-24 2010-09-30 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anticorps anti-mésothéline
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
KR102444399B1 (ko) * 2009-06-03 2022-09-16 이뮤노젠 아이엔씨 메이탄시노이드의 제조방법
AR086363A1 (es) 2011-04-21 2013-12-11 Bayer Ip Gmbh Conjugados de principio activo-ligante (adc) y el uso de los mismos
EP3060256B1 (fr) 2013-10-25 2019-05-08 Bayer Pharma Aktiengesellschaft Nouvelle formulation stable

Also Published As

Publication number Publication date
CU23929B1 (es) 2013-07-31
BRPI1014637A2 (pt) 2019-04-16
CY1123165T1 (el) 2021-10-29
JP2017039735A (ja) 2017-02-23
MX2011011365A (es) 2012-09-28
NZ596013A (en) 2013-11-29
US10647779B2 (en) 2020-05-12
PE20120556A1 (es) 2012-05-09
CA2760114C (fr) 2017-11-21
US20180201690A1 (en) 2018-07-19
SG175254A1 (en) 2011-11-28
CN102458477B (zh) 2016-08-24
PT2424569T (pt) 2018-01-11
AU2010243942B2 (en) 2015-01-29
US20170327589A1 (en) 2017-11-16
HUE049795T2 (hu) 2020-10-28
PL2424569T3 (pl) 2018-03-30
US10781263B2 (en) 2020-09-22
UA106492C2 (uk) 2014-09-10
EP3292874A1 (fr) 2018-03-14
GT201100269A (es) 2013-08-21
JP5616433B2 (ja) 2014-10-29
KR20120031265A (ko) 2012-04-02
JP6395783B2 (ja) 2018-09-26
MY158624A (en) 2016-10-31
DK3292874T3 (da) 2020-06-02
CN106177984B (zh) 2019-12-24
AR076284A1 (es) 2011-06-01
HUE037853T2 (hu) 2018-09-28
ECSP11011423A (es) 2011-11-30
LT2424569T (lt) 2018-02-12
ZA201107757B (en) 2012-12-27
US20150322160A1 (en) 2015-11-12
HK1170671A1 (zh) 2013-03-08
LT3292874T (lt) 2020-06-10
TW201105351A (en) 2011-02-16
JP2015042174A (ja) 2015-03-05
UY32560A (es) 2010-11-30
PT3292874T (pt) 2020-05-15
SI2424569T1 (en) 2018-02-28
BRPI1014637B1 (pt) 2021-08-24
HN2011002834A (es) 2013-10-28
RU2011148220A (ru) 2013-06-10
WO2010124797A8 (fr) 2011-12-08
SI3292874T1 (sl) 2020-07-31
AU2010243942A1 (en) 2011-11-10
WO2010124797A1 (fr) 2010-11-04
CN102458477A (zh) 2012-05-16
DOP2011000331A (es) 2011-11-15
ES2790732T3 (es) 2020-10-29
EP2424569B1 (fr) 2017-10-18
TN2011000547A1 (en) 2013-05-24
PL3292874T3 (pl) 2020-10-19
US20120189644A1 (en) 2012-07-26
TWI472343B (zh) 2015-02-11
CA2760114A1 (fr) 2010-11-04
CU20110200A7 (es) 2012-06-21
UA116874C2 (uk) 2018-05-25
IL215769A (en) 2016-12-29
US9084829B2 (en) 2015-07-21
NO2424569T3 (fr) 2018-03-17
JO3486B1 (ar) 2020-07-05
HRP20200884T1 (hr) 2020-09-04
US20200377614A1 (en) 2020-12-03
JP2012525342A (ja) 2012-10-22
ES2655273T3 (es) 2018-02-19
CN106177984A (zh) 2016-12-07
TW201529084A (zh) 2015-08-01
AU2010243942A8 (en) 2012-06-07
CY1119738T1 (el) 2018-06-27
IL215769A0 (en) 2012-01-31
HRP20180015T1 (hr) 2018-02-09
EP2424569A1 (fr) 2012-03-07
EP3292874B1 (fr) 2020-04-08
KR101681795B1 (ko) 2016-12-01
CO6450601A2 (es) 2012-05-31
CL2011002681A1 (es) 2012-07-13
DK2424569T3 (en) 2018-01-15
CR20110566A (es) 2012-02-20

Similar Documents

Publication Publication Date Title
MA33229B1 (fr) Immunoconjugues anti-mesotheline et leurs utilisations
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
Sutherland et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
EA200970130A1 (ru) Антагонистическое антитело для лечения рака
KR102336566B1 (ko) 클라우딘 18.2에 대한 항체를 포함하는 약물 접합체
MA34546B1 (fr) Agents de liaisons à cd33
Iyer et al. Antibody drug conjugates—Trojan horses in the war on cancer
MA32126B1 (fr) Anticorps et immunoconjugués anti-cd79b et leurs procédés d'utilisation
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
Huang et al. Anti‐tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate‐specific membrane antigen
WO2004018000A3 (fr) Compositions et methodes de traitement du cancer a l'aide d'immunoconjugues cytotoxiques d'anticorps du cd44 et d'agents chimiotherapeutiques
US20250281634A1 (en) Conjugates comprising a phosphorus (v) and a drug moiety
MA31662B1 (fr) Anticorps chimeres et humanises anti-cd44 influencant la cytotoxicite des cellules cancereuses
MA33601B1 (fr) Molécules d'anticorps anti-gcc, compositions et procédés apparentés
MY209745A (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MA52962B1 (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
Barreca et al. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
Advani New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors
PH12021552379A1 (en) Anti-egfrviii antibodies and antigen-binding fragments thereof
MA32815B1 (fr) Composition pour cibler des cellules dendritiques
MA34487B1 (fr) Compositions d'anticorps anti-vegfr-3.
MX2025009383A (es) Anticuerpos anti antigeno de membrana especifico de prostata (psma), conjugados y metodos de uso
Guffroy et al. Improving the safety profile of ADCs
Kim et al. Antibody-immunotoxin Conjugate Using FcBP-mediated Photoconjugation to Treat Cancer